Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

BACKGROUND: In Her2-positive advanced breast cancer, the upfront use of trastuzumab is well established. Upon progression on first-line therapy, patients may be switched to lapatinib. Others however remain candidates for continued antibody treatment (treatment beyond progression). Here, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Rupert, De Vries, Catharina, Pluschnig, Ursula, Dubsky, Peter, Bago-Horvath, Zsuzsanna, Gampenrieder, Simon P, Rudas, Margaretha, Mader, Robert M, Rottenfusser, Andrea, Wiltschke, Christoph, Gnant, Michael, Zielinski, Christoph C, Steger, Guenther G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770076/
https://www.ncbi.nlm.nih.gov/pubmed/19835621
http://dx.doi.org/10.1186/1471-2407-9-367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770076/
https://www.ncbi.nlm.nih.gov/pubmed/19835621
http://dx.doi.org/10.1186/1471-2407-9-367

Ejemplares similares